CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS...
Exhibit 10.8
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER
THE SECURITIES ACT OF 1933, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
THIRD AMENDMENT
to the
LICENSE AND COMMERCIALISATION AGREEMENT
by and between
Xxxxxxxxxxx 0
00000 Xxxxx
Xxxxxxx
(Hereinafter referred to as “BioTie”)
and
X. XXXXXXXX A/S
Ottiliavej 9
OK 2500 Valby
Denmark
(Hereinafter referred to as “Lundbeck”)
(Hereinafter each also referred to as “Party” or together as “Parties”)
| Whereas: | On 23 May 2007 BioTie and Lundbeck entered into a License and Commercialisation Agreement (hereinafter the “Agreement”) regarding the commercialisation of Nalmefene, a specific opioid receptor antagonist developed by BioTie and its collaborators for the treatment of substance abuse disorders such as alcoholism and obsessive compulsive disorders, including but not limited to pathological gambling. | |
| Whereas: | With this third amendment to the Agreement (hereinafter the “Amendment”) the Parties desire to extend the geographical territory of Lundbeck’s rights under the Agreement to cover also the Republic of Turkey. | |
NOW THEREFORE, the Parties hereby agree as follows:
1 (2)
CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER
THE SECURITIES ACT OF 1933, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL
HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
| 1. | GENERAL |
The Parties hereby acknowledge and agree to include this Amendment to be an integral part of the Agreement and extend, supplement, vary, change, modify and amend the Agreement as set forth herein. The change shall become effective only upon payment of the execution fee referred to in Section 3 below.
| 2. | AMENDMENTS TO THE AGREEMENT |
The following Section of the Agreement shall be amended as set forth herein. The amendment below includes the complete text of the Section and replaces the previous text of the Section in its entirety.
| 2.1 | Section 1.1.63 |
““Territory”– the world, excluding
| • | North- and South Korea.” |
| 3. | EXECUTION FEE |
No later than five (5) days following the signing of this Amendment Lundbeck shall pay to BioTie a fixed sum of [*****] to BioTie’s bank account in [*****].
| 4. | MISCELLANEOUS |
All other terms of the Agreement (including previous amendments) shall remain unchanged and in full force and effect. This Amendment shall come into force when it has been duly signed by both Parties.
In Copenhagen, Denmark and Turku, Finland on the dates set forth below.
| BIOTIE THERAPIES CORP. | X. XXXXXXXX A/S | |||
| /s/ Timo Veromaa |
/s/ Anders Götzsche | |||
| Timo Veromaa | Anders Götzsche | |||
| President and CEO | EVP, Finance, IT & Communication | |||
| On th day of March 2009 | On 3 day of April 2009 | |||
2 (2)
